Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pipeline Watch: Phase III Starts With Atezolizumab, CNTX-4975 And WTX101

Feb 23 2018

• By John Davis

Pipeline Watch regular column feature image

Related Companies

Merck & Co., Inc.

Gilead Sciences, Inc.

Roche Holding AG

Novo Nordisk A/S

AbbVie Inc.

Eli Lilly and Company

Evolus, Inc.

Mesoblast Limited

Aimmune Therapeutics, Inc.

CytoDyn, Inc.

Dermira Inc.

Boehringer Ingelheim GmbH

Bristol Myers Squibb Company

Novartis AG

Centrexion Therapeutics Corporation

Vertex Pharmaceuticals Incorporated

Wilson Therapeutics AB

Incyte Corporation

Seikagaku Corporation

Ferring Pharmaceuticals

Amgen, Inc.

Sanofi

Societal CDMO, Inc.

Apellis Pharmaceuticals, Inc.

Fresh Tracks Therapeutics, Inc.

Gamida Cell Ltd.

Glenmark Pharmaceuticals Limited

AnaptysBio, Inc.

Immune Pharmaceuticals Inc

Seres Therapeutics, Inc.

UCB S.A.

International AIDS Vaccine Initiative (IAVI)

Sanofi

Athenex, Inc.

Almirall SA

GW Pharmaceuticals plc

La Jolla Pharmaceutical Company

Fresh Tracks Therapeutics, Inc.

DiaMedica Therapeutics Inc.

RVL Pharmaceuticals plc

Torii Pharmaceutical Co. Ltd.

ALK Laboratorierne AS

Shionogi & Co. Ltd.

Stallergenes Greer Ltd

AstraZeneca PLC

Johnson & Johnson

LEO Pharma A/S

Neurocrine Biosciences, Inc.

MorphoSys AG

Additional Topics

Approvals Research & Development Pipeline Watch BioPharmaceutical

More from Pipeline Watch

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window